Satellos Bioscience is a clinical-stage biotech company developing small molecule drugs to treat severe, progressive muscle diseases, with its lead program focused on Duchenne muscular dystrophy (DMD). DMD is a fatal genetic disorder caused by the absence of the dystrophin protein, which disrupts muscle stem cell function and progressively destroys the muscle's ability to repair itself. Unlike existing DMD therapies that attempt to restore or replace dystrophin, Satellos targets the upstream regeneration failure directly. Satellos' lead drug candidate, SAT-3247, is an orally administered small molecule that inhibits the AAK1 kinase in the Notch signaling pathway, aiming to restore asymmetric stem cell division and muscle regeneration. Critically, SAT-3247's mechanism is mutation-agnostic, meaning it could apply to the full DMD patient population — unlike exon-skipping therapies, which only work in patients with specific mutations. SAT-3247 is currently in two ongoing clinical studies: TRAILHEAD, an open-label adult DMD study, and BASECAMP, a Phase 2 pediatric study. Satellos has secured FDA Orphan Drug and Rare Pediatric Disease Designations for SAT-3247. The company generates no revenue and funds operations through capital raises. Its most likely near-term monetization path is a licensing or co-development deal with a larger pharma partner, though independent commercialization and M&A are also options. Beyond DMD, Satellos is targeting follow-on indications including FSHD, with a Phase 2 trial filing anticipated in 2026.